Figure 7

TSG attenuates the binding of nuclear factor-κB (NF-κB) to its DNA element in BV-2 cells. (A) Quantitative analysis of the effect of TSG on the binding of NF-κB to its DNA element in BV-2 cells (n = 5, **P < 0.01 versus the lipolysaccharide (LPS) alone-treated group). (B) ChIP assays showed that TSG treatment (50 μM, 30 minutes) markedly reduced the binding of NF-κB to the inducible nitric oxide (iNOS) promoter in LPS-treated cells. The chromatin was immunoprecipitated by using the anti-NF-κB p65 antibody. (C) Quantitative analysis of the effect of TSG on the binding of NF-κB to the iNOS promoter in BV-2 cells (n = 3, **P < 0.01 versus control). NS, no significance. All data were shown as mean ± standard error.